Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Rebecca Shatsky, Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian, Butch Tsiatis, Anne M. Wallace, A. Jo Chien, Erica Stringer-Reasor, Judy C. Boughey, Coral Omene, Mariya Rozenblit, Kevin Kalinsky, Anthony Elias, Christos Vaklavas, Heather Beckwith, Nicole Williams, Mili Arora, Chaitali Nangia, Evanthia T. Roussos Torres, Brittani Thomas, Kathy S. Albain, Amy S. Clark, Carla I. Falkson, Dawn L. Hershman, Claudine Isaacs, Alexandra Thomas, Jennifer F. Tseng, Amy Sanford, Kay T. Yeung, Sarah G Boles, Yunni Yi Chen, Laura A. Huppert, Nusrat Jahan, Catherine Parker, Karthik V. Giridhar, Frederick M. Howard, Mallory Blackwood, Tara Sanft, Wen Li, Natsuko Onishi, Adam L. Asare, Philip Beineke, Peter Norwood, Lamorna Brown Swigart, Gillian L. Hirst, Jeffrey B. Matthews, Brian A. Moore, W. Fraser Symmans, Elissa R. Price, Diane Heditsian, Barbara LeStage, Jane Perlmutter, Paula R. Pohlmann, Angela DeMichele, Douglas Yee, Laura van ‘t Veer, Nola M. Hylton, Laura J. Esserman